NRXP Faces Nasdaq Delisting for Bid Price Non-Compliance
Ticker: NRXPW · Form: 8-K · Filed: Feb 2, 2024 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 8-K |
| Filed Date | Feb 2, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | bearish |
Complexity: simple
Sentiment: bearish
Topics: delisting, regulatory-filing, compliance, stock-exchange
TL;DR
**NRXP got a delisting notice from Nasdaq for low stock price.**
AI Summary
NRX Pharmaceuticals, Inc. (NRXP) announced on February 1, 2024, that it received a notice from the Nasdaq Stock Market regarding its failure to meet the minimum bid price requirement. This means NRXP's common stock and warrants are at risk of delisting from Nasdaq. This matters to investors because delisting could significantly reduce the stock's liquidity and make it harder to trade, potentially leading to a further decline in share price.
Why It Matters
Delisting from Nasdaq would severely impact NRXP's stock liquidity and investor confidence, making it a much riskier investment.
Risk Assessment
Risk Level: high — The risk of delisting poses a significant threat to the stock's value and tradability, indicating severe underlying issues.
Analyst Insight
Investors should carefully evaluate the implications of potential delisting on NRXP's liquidity and future prospects, considering the increased risk and potential for further share price depreciation.
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — the registrant facing delisting
- Nasdaq Stock Market (company) — the exchange from which NRXP may be delisted
- February 1, 2024 (date) — date of the earliest event reported regarding the delisting notice
FAQ
What is the primary reason NRX Pharmaceuticals, Inc. filed this 8-K?
NRX Pharmaceuticals, Inc. filed this 8-K because it received a notice from the Nasdaq Stock Market regarding its failure to satisfy a continued listing rule or standard, specifically the minimum bid price requirement.
What specific financial instruments of NRX Pharmaceuticals, Inc. are affected by this notice?
The notice affects NRX Pharmaceuticals, Inc.'s common stock and warrants, as indicated by the XBRL tags 'us-gaap:CommonStockMember' and 'us-gaap:WarrantMember' associated with the February 1, 2024 date.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 1, 2024, which is the date NRX Pharmaceuticals, Inc. received the delisting notice.
What is the Commission File Number for NRX Pharmaceuticals, Inc.?
The Commission File Number for NRX Pharmaceuticals, Inc. is 001-38302.
Where is NRX Pharmaceuticals, Inc.'s principal executive office located?
NRX Pharmaceuticals, Inc.'s principal executive office is located at 1201 Orange Street, Suite 600, Wilmington, Delaware, 19801.
Filing Stats: 509 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-02-02 16:37:48
Key Financial Figures
- $0.001 — h registered Common Stock, par value $0.001 per share NRXP The Nasdaq Stock Mar
Filing Documents
- tm245109d1_8k.htm (8-K) — 26KB
- 0001104659-24-010087.txt ( ) — 238KB
- nrxp-20240201.xsd (EX-101.SCH) — 3KB
- nrxp-20240201_def.xml (EX-101.DEF) — 26KB
- nrxp-20240201_lab.xml (EX-101.LAB) — 36KB
- nrxp-20240201_pre.xml (EX-101.PRE) — 25KB
- tm245109d1_8k_htm.xml (XML) — 5KB
01. Notice
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 23, 2024, NRx Pharmaceuticals, Inc. (the "Company") announced in a Current Report on Form 8-K that the Hearings Panel of The Nasdaq Stock Market LLC ("Nasdaq") had granted the Company's request for an exception to the Nasdaq listing rules until April 16, 2024 to demonstrate compliance with Nasdaq Listing Rule 5450(a)(1) subject to certain conditions, including the Company filing all necessary documentation required to transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market on or before January 19, 2024. On February 1, 2024, Nasdaq informed the Company that it had approved the Company's application to transfer its listing and that the Company's securities were transferred to The Nasdaq Capital Market at the opening of business on January 19, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: February 2, 2024 By: /s/ Stephen Willard Name: Stephen Willard Title: Acting General Counsel